Sapacitabine is under clinical development by Cyclacel Pharmaceuticals and currently in Phase III for Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia). According to GlobalData, Phase III drugs for Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) have a 38% phase transition success rate (PTSR) indication benchmark for progressing into Pre-Registration. GlobalData’s report assesses how Sapacitabine’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Sapacitabine overview
Sapacitabine is under development for the treatment of relapsed/refractory acute myeloid leukemia (AML), myelodysplastic syndromes (MDS), breast cancer, ovarian cancer and pancreatic cancer. It is administered through oral route. Sapacitabine is pyrimidine analogue prodrug with potential antineoplastic activity. Sapacitabine target DNA polymerase and acts through a dual mechanism, interfering with DNA synthesis. It is based on genomic technology. The drug candidate was also under development for the treatment of non-small cell lung cancer (NSCLC), cutaneous T cell lymphoma (CTCL), chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL).
Cyclacel Pharmaceuticals overview
Cyclacel Pharmaceuticals (Cyclacel) is a biopharmaceutical company that develops oral therapies. The company develops small molecule drugs that target various phases of cell cycle control for the treatment of cancer and other serious diseases. Its products include sapacitabine, seliciclib, PLK inhibitor and CDK inhibitor. Cyclacel’s sapacitabine is the drug candidate used to treat the patients with acute myeloid leukemia. Cyclacel seliciclib is an orally available, cyclin dependent kinase inhibitor. It offers products for the treatment of anti-infective, autoimmune, cardiovascular, ophthalmic and other non-oncology indications. The company operates in the US and the UK. Cyclacel is headquartered in Berkeley Heights, New Jersey, the US.
For a complete picture of Sapacitabine’s drug-specific PTSR and LoA scores, buy the report here.
Subscribe to our Newsletter
Get industry leading news, data and analysis delivered to your inbox
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.
